AbbVie Seeks FDA Approval for Etentamig in Multiple Myeloma Treatment

AbbVie has submitted a Biologics License Application (BLA) to the U.S. FDA for etentamig, a bispecific antibody, targeting relapsed or refractory multiple myeloma in adults. This submission represents a potential new therapeutic option for patients with this chronic blood cancer, moving closer to regulatory review for market availability.